Oncopeptides uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The product is currently not marketed in the US, due to regulatory hurdles. Oncopeptides has an ongoing dialogue with the FDA regarding the regulatory path forward.
Proprietary technology platforms
Oncopeptides is developing several new compounds based on the proprietary technology platforms, Peptide Drug Conjugate (PDC) and Small Polypeptide based Killer Engagers (SPiKE).
Listing and location
Oncopeptides AB (publ) is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
The headquarters is in Stockholm, Sweden, and a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.